Sedasys Post Approval Study Users Response to System Alarms
Open-Label Post Approval Study of the SEDASYS System User Response to System Alarms
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ohio
-
Toledo, Ohio, United States, 43617
- ProMedica Toledo Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) I and II
- male and female
- Scheduled for routine colonoscopy or EGD
- ≥18 years of age
- Able to read, speak, and understand English
Exclusion Criteria:
- Physical or psychological condition which would impair trial participation, at the discretion of the PI
- BMI ≥ 35
- Pregnancy or lactation
- Known or suspected hypersensitivity to propofol or fentanyl
- Use of a fentanyl patch
- Allergies to eggs, egg products soybeans or soy products
- Diagnosis of sleep apnea
- Gastroparesis
- Full stomach at the time of procedure
- Participation in any other investigational device or drug study within 30 days of enrollment
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
SEDASYS System
|
propofol sedation with the SEDASYS System
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent of documented responses/actions taken in response to SEDASYS System alarms (oxygen desaturation, apnea, hypotension, and bradycardia alarms)
Time Frame: <24 hours, i.e., for duration of study procedure
|
<24 hours, i.e., for duration of study procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Fraction of users responses/actions to oxygen desaturation, apnea, hypotension, and/or bradycardia alarms deemed sufficient by Endpoint Adjudication Committee (EAC)
Time Frame: assessment of sufficient alarms will be reviewed by EAC after 100, 400, and 866 subjects completed the study
|
assessment of sufficient alarms will be reviewed by EAC after 100, 400, and 866 subjects completed the study
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: James F Martin, PhD, Ethicon Endo-Surgery, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SED-14-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.